Meeting
2020 ASCO Virtual Scientific Program
Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.
Authors
Taiki Hakozaki
Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
Taiki Hakozaki , Corentin Richard , Yusuke Okuma , Lisa Derosa , Arielle Elkrief , Laurence Zitvogel , Bertrand Routy , Yukio Hosomi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3095)
DOI
10.1200/JCO.2020.38.15_suppl.3095
Abstract #
3095
Poster Bd #
159
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Association between immune-related adverse events and microbiome composition in patients with advanced non–small cell lung cancer treated with immunotherapy.
First Author: Marion Tonneau
Poster
2023 ASCO Annual Meeting
Association between duration of immunotherapy and overall survival in advanced non–small-cell lung cancer.
First Author: Lova Sun
Poster
2022 ASCO Annual Meeting
Immune-related adverse events and immunotherapy efficacy in patients with cancer: A retrospective study.
First Author: Lyndsey L Prather
Poster
2022 ASCO Annual Meeting
Association between lung immune prognostic index, microbiome, and immunotherapy outcomes in non–small cell lung cancer.
First Author: Edouard Auclin